| Connie S Jones, MD | |
|
78 Medical Center Dr, Fishersville, VA 22939-2332 | |
| (800) 249-5835 | |
| Not Available |
| Full Name | Connie S Jones |
|---|---|
| Gender | Female |
| Speciality | Anesthesiology |
| Experience | 21 Years |
| Location | 78 Medical Center Dr, Fishersville, Virginia |
| Accepts Medicare Assignments | Yes. She accepts the Medicare-approved amount; you will not be billed for any more than the Medicare deductible and coinsurance. |
| Identifier | Type | State | Issuer |
|---|---|---|---|
| 1477642841 | NPI | - | NPPES |
| Facility Name | Location | Facility Type |
|---|---|---|
| Augusta Health | Fishersville, VA | Hospital |
| Group Practice Name | Group PECOS PAC ID | No. of Members |
|---|---|---|
| Augusta Medical Group | 3678632544 | 320 |
News Archive
Amorfix Life Sciences Ltd. today announced that it has entered into a licensing agreement granting Biogen Idec exclusive worldwide rights to Amorfix's lead amyotrophic lateral sclerosis (ALS) monoclonal antibodies. The antibodies have shown efficacy in animal models of ALS and Biogen Idec will now, at its expense, complete the development and prepare for clinical trials.
This month, Californians are recognized for their outstanding contributions to lifesaving therapies that treat critically ill individuals and for their donations of the blood component, plasma, that makes the creation of these unique therapies possible.
Conventional wisdom holds that adolescents are susceptible to drug use and other risk-taking behavior. However, a one-size-fits-all approach to curbing these behaviors likely will be unsuccessful, according to research to be presented Monday, May 3 at the Pediatric Academic Societies (PAS) annual meeting in Vancouver, British Columbia, Canada.
A recent study led by scientists from the United States has compared the anti-severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) antibody response among clinicians who have been immunized with Pfizer/BioNTech or Moderna coronavirus disease 2019 (COVID-19) vaccine.
› Verified 7 days ago
| Entity Name | University Of Virginia Physicians Group |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1033138250 PECOS PAC ID: 4880590728 Enrollment ID: O20040102000780 |
News Archive
Amorfix Life Sciences Ltd. today announced that it has entered into a licensing agreement granting Biogen Idec exclusive worldwide rights to Amorfix's lead amyotrophic lateral sclerosis (ALS) monoclonal antibodies. The antibodies have shown efficacy in animal models of ALS and Biogen Idec will now, at its expense, complete the development and prepare for clinical trials.
This month, Californians are recognized for their outstanding contributions to lifesaving therapies that treat critically ill individuals and for their donations of the blood component, plasma, that makes the creation of these unique therapies possible.
Conventional wisdom holds that adolescents are susceptible to drug use and other risk-taking behavior. However, a one-size-fits-all approach to curbing these behaviors likely will be unsuccessful, according to research to be presented Monday, May 3 at the Pediatric Academic Societies (PAS) annual meeting in Vancouver, British Columbia, Canada.
A recent study led by scientists from the United States has compared the anti-severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) antibody response among clinicians who have been immunized with Pfizer/BioNTech or Moderna coronavirus disease 2019 (COVID-19) vaccine.
› Verified 7 days ago
| Entity Name | Augusta Medical Group |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1245489590 PECOS PAC ID: 3678632544 Enrollment ID: O20081106000590 |
News Archive
Amorfix Life Sciences Ltd. today announced that it has entered into a licensing agreement granting Biogen Idec exclusive worldwide rights to Amorfix's lead amyotrophic lateral sclerosis (ALS) monoclonal antibodies. The antibodies have shown efficacy in animal models of ALS and Biogen Idec will now, at its expense, complete the development and prepare for clinical trials.
This month, Californians are recognized for their outstanding contributions to lifesaving therapies that treat critically ill individuals and for their donations of the blood component, plasma, that makes the creation of these unique therapies possible.
Conventional wisdom holds that adolescents are susceptible to drug use and other risk-taking behavior. However, a one-size-fits-all approach to curbing these behaviors likely will be unsuccessful, according to research to be presented Monday, May 3 at the Pediatric Academic Societies (PAS) annual meeting in Vancouver, British Columbia, Canada.
A recent study led by scientists from the United States has compared the anti-severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) antibody response among clinicians who have been immunized with Pfizer/BioNTech or Moderna coronavirus disease 2019 (COVID-19) vaccine.
› Verified 7 days ago
| Mailing Address | Practice Location Address |
|---|---|
| Connie S Jones, MD Po Box 183, Hardy, VA 24101-0183 Ph: (540) 427-4406 | Connie S Jones, MD 78 Medical Center Dr, Fishersville, VA 22939-2332 Ph: (800) 249-5835 |
News Archive
Amorfix Life Sciences Ltd. today announced that it has entered into a licensing agreement granting Biogen Idec exclusive worldwide rights to Amorfix's lead amyotrophic lateral sclerosis (ALS) monoclonal antibodies. The antibodies have shown efficacy in animal models of ALS and Biogen Idec will now, at its expense, complete the development and prepare for clinical trials.
This month, Californians are recognized for their outstanding contributions to lifesaving therapies that treat critically ill individuals and for their donations of the blood component, plasma, that makes the creation of these unique therapies possible.
Conventional wisdom holds that adolescents are susceptible to drug use and other risk-taking behavior. However, a one-size-fits-all approach to curbing these behaviors likely will be unsuccessful, according to research to be presented Monday, May 3 at the Pediatric Academic Societies (PAS) annual meeting in Vancouver, British Columbia, Canada.
A recent study led by scientists from the United States has compared the anti-severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) antibody response among clinicians who have been immunized with Pfizer/BioNTech or Moderna coronavirus disease 2019 (COVID-19) vaccine.
› Verified 7 days ago
Swen Ericson Laser, MD Anesthesiology Medicare: Medicare Enrolled Practice Location: Augusta Medical Center Anesthesia Dept, 78 Medical Center Drive, Fishersville, VA 22939 Phone: 540-427-4406 Fax: 540-427-4915 | |
Laura L Fitzpatrick, MD Anesthesiology Medicare: Accepting Medicare Assignments Practice Location: 78 Medical Center Dr, Fishersville, VA 22939 Phone: 540-332-5757 Fax: 540-332-5756 | |
Dr. Bradley J. Cashion, M.D. Anesthesiology Medicare: Accepting Medicare Assignments Practice Location: 78 Medical Center Dr, Fishersville, VA 22939 Phone: 540-332-5757 Fax: 540-332-5756 | |
Victor C Lee, Anesthesiology Medicare: Not Enrolled in Medicare Practice Location: 70 Medical Center Dr, Suite 305, Fishersville, VA 22939 Phone: 540-932-5747 Fax: 540-932-5748 | |
Kevin Charles Greer, MD Anesthesiology Medicare: Accepting Medicare Assignments Practice Location: 70 Medical Center Cir Ste 305, Fishersville, VA 22939 Phone: 540-932-5747 Fax: 540-932-5748 | |
Dr. Timothy J Nitzsche, MD Anesthesiology Medicare: Accepting Medicare Assignments Practice Location: 78 Medical Center Dr, Anesthesia Dept, Fishersville, VA 22939 Phone: 540-427-4406 Fax: 540-427-4915 | |
Dr. Edward Franklin Eisenberg, M.D. Anesthesiology Medicare: Accepting Medicare Assignments Practice Location: 78 Medical Center Dr, Augusta Health, Fishersville, VA 22939 Phone: 540-332-4326 Fax: 540-332-4339 |